Newsroom

LATEST PUBLICATIONS

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

2024-03-26T13:55:01-07:00March 20th, 2024|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

2024-03-26T13:50:51-07:00March 19th, 2024|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

2024-03-03T11:41:21-08:00March 1st, 2024|

Leveraging Standardized MRD Assays to Guide CLL Treatment

2024-01-25T10:44:11-08:00January 25th, 2024|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

2023-04-10T20:22:16-07:00March 23rd, 2023|

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

2025-12-19T18:08:11-08:00June 2nd, 2023|

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan

2025-12-29T12:29:29-08:00May 25th, 2023|

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

2023-05-11T03:12:47-07:00May 11th, 2023|

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

2023-02-23T06:28:40-08:00February 23rd, 2023|

Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)

2023-02-01T21:02:16-08:00February 1st, 2023|

AMP Europe

Jun 15-17, 2026
Tallin, Estonia
Attending
Visit Conference Website

27th Japanese Society for Laboratory Hematology

Jun 20 – 21, 2026
Naha, Japan
Exhibiting

The 30th Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer

Jun 30 – Jul 2, 2026
Hiroshima, Japan
Attending

33rd Japanese Society for Gene Diagnosis and Therapy

Jul 10 – 11, 2026
Fukuoka, Japan
Attending

CGC

Aug 1-5, 2026
Houston, TX
Exhibiting
Visit Conference Website

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

AMP Europe

27th Japanese Society for Laboratory Hematology

The 30th Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer

33rd Japanese Society for Gene Diagnosis and Therapy

CGC

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.